IRVINE, Calif., July 28 SectorWatch.biz announces theavailability of MarketStats for renal and medical device equities in the newsand driving markets today. MarketStats offers a perspective on theaforementioned equities and the opportunity for investors to respond witharticles, blogs and opinions.
Investors can view MarketStats by visiting: http://www.SectorWatch.biz --a division of FiSpace.net, a dynamic social networking site for investors.
Today's MarketStats for renal and medical device companies includeXcorporeal, Inc. (Amex: XCR), Fresenius, Inc. (NYSE: FMS), Medtronic Inc(NYSE: MDT), Varian Medical Systems (NYSE: VAR), and NxStage Medical(Nasdaq: NXTM).
For a corporate profile on Xcorporeal, Inc. (Amex: XCR) visit thefollowing link: http://www.stockupticks.com/profiles/7-26-08.html
A Roth Capital Partners' May 2008 Research Report on Xcorporeal isavailable at that page as well.
FiSpace.net is the premiere Internet destination for stock market readersand writers, allowing individuals to post blogs, articles, messages and morein organized sector channels, allowing for the effective exchange of ideas. Byposting content on FiSpace.net individuals can acquire F.A.N.S. (FinancialNetworked Subscribers) who help increase the author's influence and standingon the site in an unprecedented way.
SectorWatch.biz is powered by Market Pathways, a leader in therepresentation of Small Cap equities for nearly thirty years. Market Pathways'analyst Brian Kelly holds CRD #2880975.
Statements herein may contain forward-looking statements and are subjectto significant risks and uncertainties affecting results. SectorWatch.biz,FiSpace.net and StockUpTicks.com are properties of Market Pathways FinancialRelations Inc. (MP). MP provides no assurance as to the subject company'splans or ability to effect proposed actions and cannot project capabilities,intent, resources, or experience. The subject companies have not alwaysapproved the statements made in this report. This report is neither asolicitation to buy nor an offer to sell securities but is for informationpurposes only and should not be used as the basis for any investment decision.MP is not an investment advisor, analyst or licensed broker dealer and thisreport is not investment advice. MP has been paid ten thousand dollars byAtlanta Capital for preparation and distribution of this report and otheradvertising services over a thirty day period. This constitutes a conflict ofinterest as to MP's ability to remain objective in its communication regardingthe subject company.